The intronless gene encompasses 8718 base pairs and is located at 2p25.2.
Protein
The human SOX11 protein and functional domains. Numbers indicate the amino acid positions at the beginning and the end of each domain. The grey bar shows the High-MobilityGroup (HMG) box DNA-binding domain; and the dark blue bar shows the TransActivation Domain (TAD).
Description
The human SOX11 protein has 441 amino acids and 46.7 kDa molecular weight. It contains two functional domains: a Sry-related high-mobility group (HMG) box (Sox) DNA-binding domain, located in the N-terminal third (47-122), and a transactivation domain (TAD), located at the C-terminus (408-441) (Dy et al., 2008; Penzo-Méndez, 2009 ).
Expression
SOX11 is widely expressed during organogenesis in the embryo and is highly expressed in the central and peripheral nervous system of the human fetus (Jay et al., 1995; Sock et al., 2004) . SOX11 expression is more restricted by birth, and low transcript levels of SOX11 were detected in adult colon, small intestine, heart and brain (Weigle et al., 2005) . High level of SOX11 mRNA is only present in normal prostate tissue (Brennan et al., 2009 ).
Localisation
Nucleus.
Function
SOX11 contains domains that may function as transcriptional activators or repressors and is a member of the group C SOX transcription factor family. It appears to have critical roles in embryonic neurogenesis and development of many organ systems including heart, palate and eyelids (Sock et al., 2004) . SOX11 can, together with SOX4, regulate the differentiation of neuronal progenitors (Bergsland et al., 2006) . SOX11 is involved in the transcriptional regulation of specific gene expression programs in adult neurogenesis at the stage of the immature neuron (Haslinger et al., 2009 ). SOX11 controls morphological maturation such as neurite growth (Jankowski et al., 2006) and modulates the regeneration following peripheral nerve injury (Jankowski et al., 2009 ). The class-III beta-tubulin gene TUBB3 is the first and still the unique gene to be identified as a direct target of SOX11 (Dy et al., 2008) . SOX11 has been suggested to bind and regulate LINE retrotransposons (Tchénio, 2000) .
Homology
The two domains are highly conserved regions between species (from human to fly). In the SOX C group, consisting of SOX4, SOX11 and SOX12, the HMG box and C33 domains are more highly conserved among Sox4 orthologues and SOX11 orthologues than among SOX12.
Implicated in

Malignant glioma
Note SOX11 was identified by screening an expression database for genes highly expressed in glioblastoma multiforme (Weigle et al., 2005) . Overexpression of SOX11 can prevent tumorigenesis of glioma-initiating cells by inducing their neuronal differentiation (Hide et al., 2009) . Disease Malignant glioma comprises of the majority of primary brain tumors with 16800 new cases reported each year in USA. Prognosis SOX11 can serve as a target antigen for gliomadirected cytotoxic T lymphocytes (CTLs), and this novel CTL epitope may serve as a suitable candidate for a T cell-based immunotherapy of glioma patients (Schmitz et al., 2007) .
Medulloblastoma
Note SOX11 has been shown to be overexpressed in most classical medulloblastomas (Lee et al., 2002) . Disease Medulloblastomas are brain tumors occurred in the cerebellum.
Haematological malignancies
Note
Overexpression of SOX11 was first described as a unique marker for a specific malignant B cell lymphoma, mantle cell lymphoma (Ek et al., 2008; Wang et al., 2008) . Subsequent studies have demonstrated that Sox11 is also present in: -50% of hairy cell leukemia (Chen et al., 2009; Dictor et al., 2009) ; -25-50% of Burkitt lymphoma cases (Dictor et al., 2009; Mozos et al., 2009) ; -Almost all of B-cell lymphoblastic leukemia/lymphomas and T-cell lymphoblastic leukemia/lymphomas; -2/3 cases of T-cell prolymphocytic leukemia (Dictor et al., 2009; Mozos et al., 2009) . Prognosis Expression of SOX11 in mantle cell lymphoma is not only a new diagnostic marker but may also carry information related to the clinical and biological behaviour .
Ovarian cancer
Note SOX11 is overexpressed in many epithelial ovarian cancers, and loss of Sox11 is associated with a decreased recurrence-free survival and a more aggressive phenotype (Brennan et al., 2009 ). Prognosis SOX11 is differently expressed in epithelial ovarian cancer and is a prognostic marker.
